openPR Logo
Press release

Global Parkinson’s Disease Therapeutics Market: Effective Marketing Strategies and Growing Health Awareness to Facilitate Market Growth to 2025| AbbVie Inc, Novartis AG And F. Hoffmann-La Roche AG

07-06-2018 09:15 AM CET | Health & Medicine

Press release from: Parkinson’s Disease Therapeutics Market

Global Parkinson’s Disease Therapeutics Market: Effective

Albany, NY, 6th July : Recent research and the current scenario as well as future market potential of "Parkinson’s Disease Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" globally.

This report on Parkinson’s disease therapeutics market studies the current as well as future prospects of the market globally. Stakeholders of the market include companies and intermediaries engaged in the manufacturing, commercialization, providing therapeutic drugs for treatment of Parkinson’s disease, as well as new entrants planning to enter the market.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1772203

The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global Parkinson’s disease therapeutics market with respect to the leading market segments based on drug class, route of administration, distribution channel, and geography.

The global Parkinson’s disease therapeutics market is divided into four segments on the basis of drug class, route of administration, distribution channel, and geography. Based on drug class, the market has been further segmented into Levodopa combination, dopamine agonists, MAO-B Inhibitors, COMT Inhibitors, and others. In terms of route of administration, the market has been classified into oral, transdermal, subcutaneous, intestinal infusion, and others. The Parkinson’s disease therapeutics market has also been studied from the point of distribution channel, based on which the market has been bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy.

Each of the market segments has been extensively analyzed based on market-related factors such as increasing incidence and prevalence of Parkinson’s disease. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR) percentage for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the Parkinson’s disease therapeutics market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global Parkinson’s disease therapeutics market.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/parkinsons-disease-therapeutics-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html/toc

Geographically, Parkinson’s disease therapeutics market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2015 to 2025, along with their respective CAGR for the forecast period from 2017 to 2025, considering 2016 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. It also provides market attractiveness analysis and market share analysis of key players, thus presenting a thorough examination of the overall competitive scenario of the global Parkinson’s disease therapeutics market.

Major players operating in the global Parkinson’s disease therapeutics market are AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and UCB Inc, which exhibit the widest geographical outreach. Other prominent players operating in the global market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.

The global Parkinson’s disease therapeutics market is segmented as follows:

By Drug Class

Levodopa Combination
Dopamine Agonists
MAO-B Inhibitors
COMT Inhibitors
Others

By Route of Administration

Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Geography

North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of LATAM

Browse Report @ https://www.researchmoz.us/parkinsons-disease-therapeutics-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html

Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket Ghumare,
ResearchMoz,
90 State Street, Albany NY, United States,
Tel: +1-518-621-2074,
USA-Canada Toll Free: 866-997-4948,
Email: sales@researchmoz.us,
Follow me on : https://marketinfo247.wordpress.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Parkinson’s Disease Therapeutics Market: Effective Marketing Strategies and Growing Health Awareness to Facilitate Market Growth to 2025| AbbVie Inc, Novartis AG And F. Hoffmann-La Roche AG here

News-ID: 1112979 • Views:

More Releases from Parkinson’s Disease Therapeutics Market

Parkinson’s Disease Therapeutics Market to be at Forefront by 2025 | Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd
Parkinson’s Disease Therapeutics Market to be at Forefront by 2025 | Novartis …
ResearchMoz include new market research report "Parkinson’s Disease Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its huge collection of research reports. This report on Parkinson’s disease therapeutics market studies the current as well as future prospects of the market globally. Stakeholders of the market include companies and intermediaries engaged in the manufacturing, commercialization, providing therapeutic drugs for treatment of Parkinson’s disease, as
Global Parkinson’s Disease Therapeutics Market to 2025| AbbVie, Novartis AG, F Hoffmann-La Roche AG, Teva Pharmaceutical Industries, UCB, STADA Arzneimittel AG, Merck & Co
Global Parkinson’s Disease Therapeutics Market to 2025| AbbVie, Novartis AG, F …
Albany, NY, 15th January : Recent research and the current scenario as well as future market potential of "Parkinson’s Disease Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" globally. Parkinson’s Disease Therapeutics Market - Overview This report on Parkinson’s disease therapeutics market studies the current as well as future prospects of the market globally. Stakeholders of the market include companies and intermediaries engaged in the
Parkinson’s Disease Therapeutics Market 2017 - 2025 : Attractiveness, Analysis and Key Players- AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG,GlaxoSmithKline plc
Parkinson’s Disease Therapeutics Market 2017 - 2025 : Attractiveness, Analysis …
Researchmoz added Most up-to-date research on "Parkinson’s Disease Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its huge collection of research reports. Parkinson’s Disease Therapeutics Market - Overview This report on Parkinson’s disease therapeutics market studies the current as well as future prospects of the market globally. Stakeholders of the market include companies and intermediaries engaged in the manufacturing, commercialization, providing therapeutic drugs for

All 4 Releases


More Releases for Inhibitors

Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts
Vesicular Monoamine Transporter-2 Inhibitors (VMAT2 Inhibitors) Market to Regist …
Vesicular monoamine transporter 2 (VMAT2) is a membrane-embedded protein that is responsible for uptake of monoamines neurotransmitters such as dopamine, serotonin, norepinephrine, and histamines into the synaptic vesicles in monoaminergic neurons. Vesicular monoamine transporter proteins 2 are expressed in the central nervous system (CNS) and plays the crucial role in the signaling process between the monoamine neurons. VMAT2 is the only transporter that carries the cytoplasmic dopamine into the vesicles.
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy 1.1 Overview 1.2 History- From Tragedy to Breakthrough Major Immune Checkpoints Proteins 2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development 2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development Mechanism of Action of Immune Checkpoint Inhibitors 3.1 Cytotoxic T lymphocyte Antigen-4
Global Immune Check Point Inhibitors Market & Immune Check Point Inhibitors Clin …
Immunotherapy represents a paradigm shift in oncology therapy along the multiple fronts. Although, targeted therapy upgrades the underlying signaling defect which results in oncogenesis within the tumor. The immune checkpoint blockade is fundamentally a therapy which directed at the patient's native immune system to tilt the immune homeostasis away from self-tolerance towards cytotoxicity, with the goal of inducing antitumor immunity. The immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab
Tumor Necrosis Factor Inhibitors Market & TNF Inhibitors Clinical Pipeline Outlo …
The search for the effective therapeutic approaches in the modulation of the TNF has been focus of the research efforts. Approximately 1 Million people in the worldwide either undergoing the treatment or have been treated with the TNF inhibitors which are available in the pharmaceutical market which surrounding the indications that include the rheumatoid arthritis, psoriatic arthritis, psoriasis and inflammatory bowel diseases. The neutralization of the TNF signaling can be achieved